Navigation Links
Talecris Biotherapeutics Announces Premerger HSR Filing
Date:7/14/2010

RESEARCH TRIANGLE PARK, N.C., July 14 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today confirmed that it filed its premerger notification and report form with respect to its proposed merger with Grifols S.A. under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice on July 6, 2010. Grifols has informed Talecris that their company filed its premerger notification and report form the following day.‬

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com


'/>"/>
SOURCE Talecris Biotherapeutics Holdings Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement
2. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
4. Siemens/Talecris Win Best Partnership in the Outsourcing Excellence Awards
5. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
6. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
7. Talecris Added to NASDAQ Biotechnology Index
8. Talecris Biotherapeutics to Present at the 2010 Citi Investment Research Global Health Care Conference
9. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
10. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
11. Integrated BioTherapeutics Awarded NIAID Contract For Up to $65 Million for Development of a Vaccine against Ebola and Marburg Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 ... ... announced today that in a published evaluation of multiple immunoassay-based threat detection ... Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift Initiative, Inc ... with Compass Research . GGI's mission is to advance global health and highlight ... in need in honor of each clinical trial volunteer. The vision of GGI is ...
(Date:2/23/2017)... SAN FRANCISCO , Feb. 23, 2017 /PRNewswire/ ... and Beyond Type 1, a not-for-profit advocacy and education ... announced a grant from Beyond Type 1 to support ... 1 and other insulin-requiring diabetes.  For ... stem cell-derived cell replacement therapies with a focus on ...
(Date:2/22/2017)... ANGELES, CA (PRWEB) , ... February 22, 2017 ... ... today announced that is has acquired Kendall Research Systems, LLC (KRS) ... Technology (MIT) that develops neural interface technology for research and clinical applications. The ...
Breaking Biology Technology:
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):